Posters

Intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy

Poster Details

First Author: P.Ozdal TURKEY

Co Author(s):    K. Tekin   B. Gulpamuk   M. Teke                       

Abstract Details



Purpose:

To evaluate the efficacy and tolerability of intravitreal aflibercept injection as a treatment option in eyes with chronic central serous chorioretinopathy (CSCR).

Setting:

A single-centre prospective interventional study conducted in an specialized eye hospital which is a tertiary referral centre.

Methods:

10 eyes of 10 patients with chronic CSCR who had been followed for > 6 months after the first intravitreal injection of aflibercept were recruited for the study. The best corrected visual acuity (BCVA) and central macular thickness (CMT) values obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the injection.

Results:

The mean LogMAR BCVA was 0.70 ± 0.25 at the baseline. At the first, third, and sixth months after the injection, the mean LogMAR BCVA values were 0.39 ± 0.36, 0.32 ± 0.39 and 0.29 ± 0.34 respectively. The mean BCVA during the entire follow-up period was significantly improved compared with the baseline BCVA. Complete or partial resolution of subretinal fluid (SRF) was observed in all patients. SRF resolved completely in five (50%) and partially in 3 (30%) patients in whom additional aflibercept injection(s) were needed. Two patients recurred approximately 4 months after the baseline. In one of these 2 patients, SRF resolved completely after applying focal laser photocoagulation to the leakage area. The mean CMT was 449.30 ± 142.53 μm at baseline and was measured as 302.60 ± 72.28 μm on the first month, 294.30 ± 72.85 μm on the third, and 294.60 ± 83.84 μm on the sixth month post-injection. The mean CMT during the entire follow-up period decreased significantly compared with the baseline CMT. No patients experienced any serious ocular or systemic adverse events over the course of the study.

Conclusions:

Intravitreal aflibercept is an effective and well-tolerated agent to improve the BCVA and reduce the CMT in patients with chronic CSCR.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy